No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ): Independent Director Han Jiajun has passed away.
Gelonghui reported on February 11 that Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) announced that the Board of Directors learned that independent director Ms. Han Jiajun passed away due to illness on February 10, 2025. During her tenure as an independent director, member of the audit committee, and chairwoman of the nomination committee, Ms. Han Jiajun worked diligently and responsibly, fulfilling her duties and obligations as an independent director with sincerity and loyalty. The Board of Directors expresses gratitude for Ms. Han Jiajun's contributions to the company and mourns her passing.
Should You Be Worried About Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) 1.4% Return On Equity?
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Market Cap Rose CN¥532m Last Week; Retail Investors Who Hold 58% Profited and so Did Insiders
tonghua golden-horse pharmaceutical industry co,ltd (000766.SZ): Subsidiaries are expected to invest no more than 0.1 billion yuan to build an artificial musk breeding base
On November 27, Ge Long Hui reported that tonghua golden-horse pharmaceutical industry co,ltd (000766.SZ) announced that based on future development global strategy and business development needs, to further enhance the comprehensive competitiveness of Yongkang Pharmaceutical, it agreed to implement the construction of an artificial musk breeding base focused on musk as the core fulcrum, with an expected investment amount not exceeding 100 million yuan. The project plans to complete the construction of the pens and supporting facilities, equipment procurement, and introduction of breeding stock by the end of June 2025. Through this base construction project, the scale of deer breeding will be expanded, extending the musk industry chain to achieve 'deer breeding, raw material extraction,'
Optimistic Investors Push Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Shares Up 27% But Growth Is Lacking
